ACCESS Newswire·Sep 8, 2026, 4:05 PM ET

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics' Board authorized a $300 million share repurchase program for its outstanding common stock.
Repurchases will be funded using existing cash, marketable securities, & royalty payments from collaborations with Takeda & Johnson & Johnson.
As of June 30, 2026, the company held $849.5 million in liquid assets, excluding a $200 million opt-out payment & a $75 million milestone payment from Takeda expected in Q4 2026.
The program has no obligation to acquire specific share quantities & may be modified, suspended, or discontinued at any time without notice.
Stock repurchases may occur via open market transactions or Rule 10b5-1 trading plans based on market conditions & other factors.
The company currently markets two FDA-approved medicines: ICOTYDE (icotrokinra) for psoriasis & MIMRYLO (rusfertide) for polycythemia vera.
ICOTYDE was launched in the U.S. in March 2026 & is in Phase 3 trials for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
MIMRYLO is approved for erythrocytosis in polycythemia vera patients & is commercialized by Takeda worldwide.
Protagonist maintains additional pipeline programs including oral IL-17 antagonists, obesity agonists, & new IL-4 & amylin discovery initiatives.